SARS-CoV-2 vaccination and phase 1 cancer clinical trials

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

(2020) A. Bayle et al.   ANNALS OF ONCOLOGY

Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus

(2020) G. Curigliano et al.   ANNALS OF ONCOLOGY

Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study

(2020) Amit Sud et al.   LANCET ONCOLOGY

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I trials as valid therapeutic options for patients with cancer

(2019) Jacob J. Adashek et al.   Nature Reviews Clinical Oncology

Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

(2011) O. E. Yri et al.   BLOOD